Citrulline Malate 2:1, 3000mg
Food supplement declared in France, decision dated 11 June 2026
Citrulline Malate 2:1, 3000mg (Applied Nutrition) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: L-citrulline malate. None of the rules we check flags an issue with its declared composition.
- Brand
- Applied Nutrition
- Food business operator placing the product on the market
- Olivit Sp. z o.o.
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Powder
- Daily dose
- 1 c. à mesurer
- Intended populations
- Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women
- Objectives stated by the manufacturer (these are not authorised claims)
- Sport
Declaration 367506, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Other active ingredients
| Name | Per day |
|---|---|
| L-citrulline malate | not declared |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Brand : Applied Nutrition
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Citrulline Malate 2:1, 3000mg (Applied Nutrition): composition and regulation”, https://compoatlas.com/en/supplements/products/367506-citrulline-malate-2-1-3000mg, updated 15 November 2026.